Ucci-Hem-17-01- Feasibility And Safety Of Intrathecal Rituximab Added To Standard Intrathecal Prophylaxis To Prevent Cns Relapse For Cd 20 Positive Non Hodgkin Lymphoma
Posted Date: Jun 11, 2019
- Investigator: Tahir Latif
- Specialties: Cancer, Lymphoma, Oncology
- Type of Study: Drug
The goal of this study is to determine the feasibility and safety of adding intrathecal rituximab to Central Nervous System (CNS) prophylaxis with intrathecal methotrexate for Diffuse Large B cell Lymphoma patients considered at high-risk of Central nervous system relapse.
Criteria:
To Be Eligible: Patients Must Be 18 Years Of Age Or Older, No Uncontrolled Infection Or Active Malignancy, Must Be Nonpregnant.
Keywords:
Non-Hodgkin Lymphoma, Lymphoma
For More Information:
Uccc Cancer Center
513-584-7698
cancer@uchealth.com